- AbbVie’s ELAHERE® drug demonstrated positive Phase 2 trial results for recurring ovarian cancer, highlighting progress in its oncology pipeline.
- Guggenheim reiterated a “Buy” rating for [ABBV:NYSE] and increased its price target to $249, signaling strong analyst confidence.
- The updated price target suggests a potential upside of approximately 18.49% from the stock’s price at the time of the analyst’s report.
[ABBV:NYSE] is a global biopharmaceutical company. It focuses on discovering, developing, and delivering innovative medicines for complex and serious diseases. AbbVie’s work spans areas like immunology and oncology, where it competes with other major pharmaceutical firms to bring new treatments to market.
As highlighted by PR Newswire, AbbVie recently presented positive late-breaking results from its Phase 2 trial for the drug ELAHERE®. The study evaluates the drug’s potential for treating patients with a specific type of recurring ovarian cancer. This development showcases the company’s progress in its oncology pipeline.
This positive clinical news is reflected in analyst sentiment. The firm Guggenheim reiterated its “Buy” rating for [ABBV:NYSE]. It also raised its price target on the stock to $249 from the previous target of $242, signaling increased confidence in the company’s future performance.
A price target is an analyst’s projection of a stock’s future price. When Guggenheim set the new $249 target, [ABBV:NYSE]‘s stock price was $210.15. This new target suggests a potential upside, or increase in value, of approximately 18.49% from its price at that time.
The trial tested ELAHERE® in combination with another drug, followed by ELAHERE® alone. Experts note these results are encouraging for patients who have limited options. However, the drug is not yet approved for this specific use in the U.S. or E.U., representing a future regulatory step.
